{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/opioid-dependence/management/assessment/","result":{"pageContext":{"chapter":{"id":"75fe82a9-9ba2-541a-80be-cd0cf879bca3","slug":"assessment","fullItemName":"Scenario: Assessment","depth":2,"htmlHeader":"<!-- begin field 3af6598d-793e-4cde-a4f8-ecb3598a2c48 --><h2>Scenario: Assessment</h2><!-- end field 3af6598d-793e-4cde-a4f8-ecb3598a2c48 -->","summary":"Covers the initial assessment of a person who uses drugs which is required before treatment can be started and covers harm reduction, child protection issues, advice about driving and follow-up.","htmlStringContent":"<!-- begin item 789a26a5-40b7-4d76-ba5b-2e89ef2cb7d2 --><!-- begin field 7d7d1855-2bb0-47df-8045-acbc015ab17f --><p>From age 16 years onwards.</p><!-- end field 7d7d1855-2bb0-47df-8045-acbc015ab17f --><!-- end item 789a26a5-40b7-4d76-ba5b-2e89ef2cb7d2 -->","topic":{"id":"ef534296-f504-5d3e-9b47-3c0f08322658","topicId":"1acd30d9-6aea-492b-a570-5fbeb05d49f5","topicName":"Opioid dependence","slug":"opioid-dependence","lastRevised":"Last revised in October 2020","chapters":[{"id":"7b9e0e1a-3aea-5219-a001-dfd22a786292","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0179729-bb50-55a3-a1dc-ca3cbd473972","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e63e1346-068d-56e6-891b-85878800d361","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"37edcefe-2b9f-5ab8-a584-be9e268559ac","slug":"changes","fullItemName":"Changes"},{"id":"b53b49f5-e58d-5325-8fee-7f9fdc057646","slug":"update","fullItemName":"Update"}]},{"id":"242f440f-b9b5-51a4-9d43-3492e963e9af","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5766349b-04fe-548c-9de5-0ff28c7803b9","slug":"goals","fullItemName":"Goals"},{"id":"2ed8ffe3-15a2-5e49-b2ad-033e1a4b5f22","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"419add6c-5149-5bbf-9be1-8854fefbccc4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01b28023-8c52-53e9-a23d-43bb73f67990","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e459f916-c763-56aa-9a4e-a3e6ef261b0f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a96bc65-6eb3-5a1c-99c3-2530b6d352f4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b1fa8640-11da-554d-9d7a-12696b906136","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28447573-cc1d-50d6-bea5-720f6d22e335","slug":"definition","fullItemName":"Definition"},{"id":"d7f47150-a2c5-57f9-88aa-5353f86fc58a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e594be8-c4df-5032-ad75-87ab56cb2c7e","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7da5320-e6b9-59fc-8e5a-558ea4c298d9","slug":"complications","fullItemName":"Complications"}]},{"id":"e747d7e1-25ca-5f67-9d22-349d2b18eddd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ee9cab5c-4665-56a2-9005-028143cc8f59","slug":"suspecting-opioid-dependency","fullItemName":"Suspecting opioid dependency"},{"id":"20c15a53-634f-5cb4-a88a-7cb5115d810b","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"f37505e6-dc82-5755-b700-7d1966f8c252","fullItemName":"Management","slug":"management","subChapters":[{"id":"75fe82a9-9ba2-541a-80be-cd0cf879bca3","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"d05968e4-f2be-5378-b462-0b129f5dc5e6","slug":"management","fullItemName":"Scenario: Management"},{"id":"00d16467-be2b-538d-8a7c-4d4045cabd6e","slug":"managing-special-circumstances","fullItemName":"Scenario: Managing special circumstances"}]},{"id":"0cf2cc09-9ca4-58a8-91c7-d64c38924b5a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ccbe88d0-314a-57fa-a61a-8a83bbfc9baf","slug":"writing-prescriptions-for-substitution-therapy","fullItemName":"Writing prescriptions for substitution therapy"},{"id":"5c859eeb-d8fd-50f5-8b18-e1a6a71ac111","slug":"methadone","fullItemName":"Methadone"},{"id":"3021db45-0a93-5ca8-a386-8d3e71abad63","slug":"buprenorphine","fullItemName":"Buprenorphine"}]},{"id":"9547692f-53b7-5f09-944d-6a4a6229dead","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0eafd778-db7f-578e-905f-1365ee1290a1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1d80b232-8932-503b-8765-30b929f15180","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"796c8942-47b7-56b5-a88a-cc0f133f5f3e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfb530c5-aa05-5f4c-9e26-43caae839601","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"955b9fba-573b-57a0-b099-cf3356d6e837","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f05fac2-c160-5e48-b55d-3898cce03ec0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0ead7d6b-f923-5852-bb7c-50aa97b9b2ff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f37505e6-dc82-5755-b700-7d1966f8c252","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"1a5bb538-62b3-513e-9080-8ba7a190f7a2","slug":"initial-assessment","fullItemName":"Initial assessment","depth":3,"htmlHeader":"<!-- begin field 27e5e40d-3685-4df2-bc2f-ebd920dd08c9 --><h3>How should I assess the person?</h3><!-- end field 27e5e40d-3685-4df2-bc2f-ebd920dd08c9 -->","summary":null,"htmlStringContent":"<!-- begin item 94ffbe5d-dd7b-4e7b-a15e-0ecb675a266c --><!-- begin field 13824197-1496-4eb5-8c15-a212b3f16e83 --><ul><li><strong>The purpose of the initial assessment is to: </strong><ul><li>Identify and respond to any emergency or acute problem.</li><li>Confirm the person is taking psychoactive substances (based on history, examination and drug testing, and through accessing any relevant additional information from clinical records).</li><li>Identify the degree of problem use or dependence.</li><li>Identify physical and mental health problems.</li><li>Identify social problems. </li><li>Assess the family history for substance use and dependence and relevant medical, psychiatric or psychosocial factors.</li><li>Determine the person's understanding of treatment options and motivation for change.</li><li>Explore and identify strengths the person can use to achieve their treatment and recovery goals.</li><li>Determine the need for substitute medication or other prescribing for dependence.</li><li>Assess risk behaviours, including those associated with injecting.</li></ul></li><li>Comprehensive assessment may need to be conducted over several sessions and is then ongoing. It may be appropriate for concerned friends, relatives, carers or other professionals already involved to attend.</li><li><strong>Take a history and ask about:</strong><ul><li>Degree of dependence (past and current) — types of psychoactive drugs used (including prescribed and over-the-counter medicines and tobacco), quantity and frequency of use, pattern of use, routes of administration (including any injecting), sources of drugs obtained and evidence for harmful use or dependence (including any experience of withdrawal syndromes).</li><li>Motivation — assess the person's understanding of treatment options and motivation for change. </li><li>Risk behaviours, including those associated with injecting:<ul><li>Supply of needles and syringes; sharing habits; knowledge of how to inject safely; correct disposal of used equipment; knowledge of HIV and hepatitis A, B, and C; issues of transmission and safer sex.</li><li>For drug-misusing parents or other adults with dependent children, obtain information on the children and any drug-related risks to which they may be exposed. </li></ul></li><li>Medical history — current or previous physical complications of drug use such as infection with blood-borne viruses or continuing related risky behaviours, liver disease, abscesses, overdoses, enduring severe physical disabilities and sexual health problems, last menstrual period (in order to consider pregnancy and contraception), last cervical smear.</li><li>Psychiatric history — current or previous psychological problems, such as personality problems and disorders, self-harm, history of abuse or trauma, depression, anxiety and severe psychiatric comorbidity (details of contact with mental health services should be recorded).</li><li>Family history of substance use and dependence and relevant medical, psychiatric or psychosocial factors.</li><li>Social problems: <ul><li>Problems in personal relationships (including with partners) and of social integration, including domestic violence and abuse, family, housing and living arrangements, education, employment, benefits and financial problems.</li><li>Childcare issues, including parenting, pregnancy and child protection.</li><li>Criminal involvement, offending and other legal issues, including arrests, fines, outstanding charges and warrants, probation, imprisonment, violent offences and criminal activity, and involvement with workers in the criminal justice system.</li><li>Consider asking sensitively, where relevant, how drug use is funded (for example, sex working, diversion of family income). </li></ul></li><li>Any drug-related risks to which the person's own children or other children in the home may be exposed to. Any important current risks should be clarified and reflected in a risk management plan. The assessment should take into consideration the: <ul><li>Effect of drug misuse on functioning, for example, intoxication, agitation.</li><li>Effect of drug-seeking behaviours, for example, leaving children unsupervised, contact with unsuitable characters.</li><li>Impact of parent’s physical and mental health on parenting.</li><li>Emotional availability to children.</li><li>Effects on family routines, for example, getting children to school on time.</li><li>Other people supporting the children, for example, family, and their fitness to provide that support.</li><li>Ability to access professional support.</li><li>Storage of illicit drugs, prescribed medication and drug-using paraphernalia.</li></ul></li><li>Past contact with treatment services — previous efforts to reduce or stop taking drugs; past contact with treatment and rehabilitation, social, medical, and community services.</li><li>Strengths, including: <ul><li>Personal, family, social and other strengths and positive networks they can use to achieve their treatment and recovery goals.</li><li>Past successes and difficulties in achieving stability or in making improvements (for example, what helped in the past and what didn’t help or what caused any relapse).</li></ul></li></ul></li><li><strong>Examine the person in order to:</strong><ul><li>Confirm evidence of drug misuse (for example, needle tracks, signs of drug intoxication or <a class=\"topic-reference internal-reference\" href=\"/topics/opioid-dependence/management/assessment/#managing-acute-withdrawal-syndrome\">withdrawal</a>).<ul><li>Injecting into the groin or neck are indications of high-risk drug use which may benefit from specialist advice or referral. </li></ul></li><li>Check for the presence of <a class=\"topic-reference internal-reference\" href=\"/topics/opioid-dependence/background-information/complications/\">complications</a>. </li><li>Assess mental health. </li><li>Assess respiratory, cardiovascular and other body systems. </li></ul></li><li><strong>Consider investigations to exclude complications </strong>— the choice of investigations is guided by clinical judgement, but may include:<ul><li>Tests for hepatitis B, and C, and HIV. </li><li>Liver, renal or thyroid function tests. </li><li>Full blood count (to exclude anaemia, signs of infection). </li><li>Neurological examination. </li></ul></li></ul><!-- end field 13824197-1496-4eb5-8c15-a212b3f16e83 --><!-- end item 94ffbe5d-dd7b-4e7b-a15e-0ecb675a266c -->","subChapters":[{"id":"ee5209d6-b8f5-5948-9a16-37819f77f966","slug":"basis-for-recommendation-bcc","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 37252f62-76b2-434d-82ab-cbcd37fa30b9 --><h4>Basis for recommendation</h4><!-- end field 37252f62-76b2-434d-82ab-cbcd37fa30b9 -->","summary":null,"htmlStringContent":"<!-- begin item bccc782e-28bb-4785-aae3-157665c1be4d --><!-- begin field b54c822f-2b92-41a2-baf4-2638ccdef742 --><p>These recommendations are based on the Department of Health and devolved administrations' guideline <em>Drug misuse and dependence: UK guidelines on clinical management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>], and the<em> </em>National Drug Strategy Australia (NDSA) <em>National guidelines for medication-assisted treatment of opioid dependence </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">NDSA, 2014</a>]. </p><!-- end field b54c822f-2b92-41a2-baf4-2638ccdef742 --><!-- end item bccc782e-28bb-4785-aae3-157665c1be4d -->","subChapters":[]}]},{"id":"ec30fe7b-49a0-507f-9b4f-179c4d164c76","slug":"assessing-suitability-for-substitution-therapy","fullItemName":"Assessing suitability for substitution therapy","depth":3,"htmlHeader":"<!-- begin field cc9d6134-f7f4-4406-8474-aa6f00abf364 --><h3>How should I assess suitability for substitution therapy?</h3><!-- end field cc9d6134-f7f4-4406-8474-aa6f00abf364 -->","summary":null,"htmlStringContent":"<!-- begin item 889799b4-a0c7-4657-b551-aa6f00abf31a --><!-- begin field ed022c83-7982-4052-9ae9-aa6f00abf364 --><ul><li><strong>Substitution therapy (maintenance or detoxification) should normally only be considered if:</strong><ul><li>Opioids are being taken on a regular basis – usually daily.</li><li>There is convincing evidence of current dependence.</li><li>The initial assessment clearly substantiates the diagnosis and the need for treatment. </li><li>The clinician is satisfied that the person may be able to comply with the prescribing regimen.</li><li>The person is not receiving an opioid prescription for management of dependence from another clinician.</li></ul></li><li><strong>If possible, check liver function tests (LFTs) at initial assessment </strong>— methadone and buprenorphine both undergo extensive metabolism in the liver. <ul><li>If the person is well, do not delay starting methadone or buprenorphine whilst waiting for the results.</li></ul></li><li><strong>If liver function tests are normal, explain that they should be monitored every 6–9 months whilst taking methadone or buprenorphine. </strong></li><li>Seek specialist advice if there is: <ul><li>Impaired hepatic function.</li><li>A marked deterioration in liver function.</li></ul></li><li>In people with advanced liver disease the risks from methadone or buprenorphine are insignificant compared to the risks from street drugs.<ul><li>People with end-stage liver disease should only be started on methadone or buprenorphine with extreme care and should be referred to a specialist.</li></ul></li></ul><!-- end field ed022c83-7982-4052-9ae9-aa6f00abf364 --><!-- end item 889799b4-a0c7-4657-b551-aa6f00abf31a -->","subChapters":[{"id":"25357373-3667-506b-bef6-2eb34c24502a","slug":"basis-for-recommendation-d06","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e3533033-8a4f-47df-a05b-aa6f00abf366 --><h4>Basis for recommendation</h4><!-- end field e3533033-8a4f-47df-a05b-aa6f00abf366 -->","summary":null,"htmlStringContent":"<!-- begin item d060aac5-8cec-46de-823a-aa6f00abf366 --><!-- begin field 8fa10542-cf21-4ab6-ae69-aa6f00abf366 --><p>These recommendations are based on the Department of Health and devolved administrations' guideline <em>Drug misuse and dependence: UK guidelines on clinical management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>], the<em> </em>National Drug Strategy Australia (NDSA) <em>National guidelines for medication-assisted treatment of opioid dependence </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">NDSA, 2014</a>], and the NHS Greater Glasgow and Clyde (NHSGGC) <em>GG&C Addiction services prescribing guidelines for medication assisted recovery with opioid replacement therapy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">NHSGGC, 2017</a>].  </p><!-- end field 8fa10542-cf21-4ab6-ae69-aa6f00abf366 --><!-- end item d060aac5-8cec-46de-823a-aa6f00abf366 -->","subChapters":[]}]},{"id":"4c9298a3-e103-54fa-a226-9f3187aca8cf","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field 74a36627-9cd3-4f11-a434-a75c00a0858e --><h3>What information and advice should I offer?</h3><!-- end field 74a36627-9cd3-4f11-a434-a75c00a0858e -->","summary":null,"htmlStringContent":"<!-- begin item 1aa74ce5-b1e5-497a-b34f-a75c00a08459 --><!-- begin field 5c84314e-53b3-46e0-904e-a75c00a0858e --><ul><li><strong>Offer information and advice on: </strong><ul><li>Immunisation against hepatitis B (and possibly hepatitis A). Ideally, vaccinate all drug users against hepatitis A and hepatitis B. <ul><li>Use the accelerated schedule for hepatitis B (given on days 0, 7, and 21) with a booster at 12 months. </li><li>Advise that partners and children should be vaccinated against hepatitis B. </li></ul></li><li>Immunisation against tetanus — ensure that the person is immunized against tetanus, as people who inject drugs are at increased risk of tetanus. Give booster doses if there is any doubt about the person's immunization status. </li><li>Blood-borne viruses and other infections — provide safer injecting advice and ensure that the person has access to clean injecting equipment, needles and syringes.</li><li>Overdose prevention training and take-home naloxone.</li><li>Contraception and safer sex — refer to a sexual health service if appropriate.</li><li>Local NHS dental services or direct referral to special care dental services if appropriate.</li></ul></li><li><strong>Offer carers specific information and advice about: </strong><ul><li>The risks from blood-borne viruses and overdose and, if appropriate, offer vaccination or referral. </li><li>Overdose and naloxone availability.</li><li>Safe storage of medicines.</li></ul></li><li><strong>Inform anyone who is opioid dependent or who is persistently using opioids that they need to inform the Driver and Vehicle Licensing Agency (DVLA) and</strong> <strong>explain that persistent use of, or dependence on, heroin, morphine, buprenorphine, or methadone will lead to refusal or revocation of a driving licence. </strong><ul><li>Some individuals may refuse to do this, and in certain circumstances confidentiality may need to be overridden. Whether the GP should breach confidence and inform the DVLA without the person's consent is a complex ethical issue. GPs may need to consult their defence union.</li><li>A licence will be considered only if the person has been free of drug use for at least 1 year for Group 1 entitlement (car and motorcycle), and at least 3 years for Group 2 entitlement (bus and lorry). An exception may be made for an individual complying fully with a consultant-supervised methadone or buprenorphine maintenance programme.</li><li>For more information, see the Driver and Vehicle Licensing Agency (DVLA) <a data-hyperlink-id=\"c29afac7-6fd3-4c4f-b22b-a98f01841eff\" href=\"https://www.gov.uk/government/publications/at-a-glance\">Guide to the Current Medical Standards of Fitness to Drive</a>.</li></ul></li><li><strong>Provide details of other sources of information</strong>, for example: <ul><li><a data-hyperlink-id=\"d7f7213c-084e-4641-9d97-a98f01841f3f\" href=\"http://www.talktofrank.com/\">FRANK</a> (the national drugs information service) provides free and confidential advice, including information on local services. Telephone: 0800 77 66 00.</li></ul></li></ul><!-- end field 5c84314e-53b3-46e0-904e-a75c00a0858e --><!-- end item 1aa74ce5-b1e5-497a-b34f-a75c00a08459 -->","subChapters":[{"id":"5b06784b-f22b-5123-9826-febd4e29265b","slug":"basis-for-recommendation-de5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d40c1ca4-773b-41e3-a76f-a75c00a0858e --><h4>Basis for recommendation</h4><!-- end field d40c1ca4-773b-41e3-a76f-a75c00a0858e -->","summary":null,"htmlStringContent":"<!-- begin item de586a36-a8f2-4665-8e65-a75c00a0858e --><!-- begin field 9c464b2d-a90f-4744-9ab5-a75c00a0858e --><p>These recommendations are based on the Department of Health and devolved administrations' guideline <em>Drug misuse and dependence: UK guidelines on clinical management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>], the Public Health England (PHE) document <em>Shooting up: infections among people who inject drugs in the UK, 2017</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">PHE, 2018a</a>], the Green book chapters on <em>Hepatitis A </em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">PHE, 2013</a>], <em>Tetanus </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">PHE, 2018b</a>], and <em>Hepatitis B</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">PHE, 2017</a>], the Driver and Vehicle Licensing Agency (DVLA) <em>Assessing fitness to drive: a guide for medical professionals</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DVLA, 2019</a>], and what CKS considers good clinical practice.</p><!-- end field 9c464b2d-a90f-4744-9ab5-a75c00a0858e --><!-- end item de586a36-a8f2-4665-8e65-a75c00a0858e -->","subChapters":[]}]},{"id":"8ba20c31-4355-53b2-b69c-8fe5acd5abb5","slug":"safeguarding-reporting-issues","fullItemName":"Safeguarding and reporting issues","depth":3,"htmlHeader":"<!-- begin field ae06ccbd-f85c-46fe-abbd-a75c00a23dd4 --><h3>How should I manage safeguarding and reporting issues?</h3><!-- end field ae06ccbd-f85c-46fe-abbd-a75c00a23dd4 -->","summary":null,"htmlStringContent":"<!-- begin item b371a6b5-a9d8-4337-b02f-a75c00a23d47 --><!-- begin field f53f65be-cf1c-4baf-8692-a75c00a23dd4 --><ul><li><strong>For drug-misusing parents or other adults with dependent children, obtain information on the children and any drug-related risks to which they may be exposed. Take into consideration: </strong> <ul><li>The effect of drug misuse on functioning (for example, intoxication, agitation).</li><li>The effect of drug-seeking behaviours (for example, leaving children unsupervised, contact with unsuitable characters).</li><li>The impact of parent’s physical and mental health on parenting.</li><li>How drug use is funded, for example, sex working, diversion of family income.</li><li>Emotional availability to children.</li><li>The effects on family routines (for example, getting children to school on time).</li><li>Other people supporting the children (for example, family) and their fitness to provide that support.</li><li>Ability to access professional support.</li><li>Storage of illicit drugs, prescribed medication and drug-using paraphernalia.</li></ul></li><li><strong>If risk of significant harm to a young person is found, involve other professionals in line with local child protection requirements and child safeguarding procedures. </strong><ul><li>For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/child-maltreatment-recognition-management/\">Child maltreatment - recognition and management</a>.</li></ul></li><li>If risk of significant harm to a vulnerable or at-risk adult is found, respond professionally and in line with local adult safeguarding procedures.</li><li><strong>A report should be made when a person first starts treatment for drug misuse </strong>— seek the person's consent and report all types of problem drug misuse (such as, opioids, benzodiazepines, central nervous system stimulants). Submit their details to: <ul><li>The National Drug Treatment Monitoring System (NDTMS) if in England. </li><li>The Chief Medical Officer of the Department of Health and Social Services if in Northern Ireland. </li><li>The Substance Misuse Database if in Scotland. </li><li>The Welsh National Database for Substance Misuse if in Wales. </li></ul></li><li>Emphasize that the national monitoring systems do not collect fully identifiable data and are confidential. Signpost the person to the NDTMS fact sheet <a data-hyperlink-id=\"d1e7a426-dda2-4432-b819-aa7100ce1f12\" href=\"https://www.ndtms.net/resources/public/PHE_NDTMS_patient_information_leaflet_V1.1.pdf\">National Drug and alcohol Treatment Monitoring System – what we do, how we use personal information, and your options</a>.</li><li><strong>Contact details for the regional centres are available in the British National Formulary,</strong> in the section <em>Guidance on prescribing: controlled drugs and drug dependence</em> (<a data-hyperlink-id=\"b475d5ad-dd2c-4248-8377-a98f0184218b\" href=\"https://bnf.nice.org.uk/\">BNF</a>).</li></ul><!-- end field f53f65be-cf1c-4baf-8692-a75c00a23dd4 --><!-- end item b371a6b5-a9d8-4337-b02f-a75c00a23d47 -->","subChapters":[{"id":"69120701-fa04-5d78-99aa-ad4d816afe76","slug":"basis-for-recommendation-3db","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 74a02960-aab3-47ee-a4a5-a75c00a23dd9 --><h4>Basis for recommendation</h4><!-- end field 74a02960-aab3-47ee-a4a5-a75c00a23dd9 -->","summary":null,"htmlStringContent":"<!-- begin item 3db8fd74-4724-4085-870d-a75c00a23dd9 --><!-- begin field 0331a7cb-c82e-4101-936d-a75c00a23dd9 --><p>These recommendations are based on the Department of Health and devolved administrations' guideline <em>Drug misuse and dependence: UK guidelines on clinical management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">Joint Formulary Committee, 2019</a>], and what CKS considers good clinical practice. </p><!-- end field 0331a7cb-c82e-4101-936d-a75c00a23dd9 --><!-- end item 3db8fd74-4724-4085-870d-a75c00a23dd9 -->","subChapters":[]}]},{"id":"cb496261-0f92-5758-8e4a-95fd0aae6043","slug":"managing-acute-withdrawal-syndrome","fullItemName":"Managing acute withdrawal syndrome","depth":3,"htmlHeader":"<!-- begin field 41d7beb1-60b4-45a4-b9a4-a75a00a5f2f7 --><h3>How should I manage acute withdrawal syndrome?</h3><!-- end field 41d7beb1-60b4-45a4-b9a4-a75a00a5f2f7 -->","summary":null,"htmlStringContent":"<!-- begin item e5fc42a9-cdbb-4e04-9735-a75a00a5f327 --><!-- begin field de8540cb-4745-48db-ae42-a75a00a5f2f7 --><ul><li><strong>Do not be </strong><strong>pressurized</strong><strong> into prescribing opioids in an unplanned manner in order to abolish withdrawal symptoms</strong> — all people require an adequate assessment. Find a balance that allows for the necessary information to be obtained efficiently without adding delay and without placing the person at risk of dropping out of treatment. The extent of the initial assessment will depend on the individual.<ul><li>A more comprehensive assessment can take place over the following weeks during treatment optimisation.</li><li>Seek specialist advice if required.</li></ul></li><li><strong>Offer referral to the local drug service for support and to discuss management options.</strong><ul><li>Heroin withdrawal symptoms reach their peak 2–4 days after the last dose of heroin. Symptoms will have subsided substantially after 5 days. </li><li>Methadone withdrawal symptoms typically reach their peak 2–4 days after the last dose of methadone (4–6 days after stopping high doses). Symptoms do not substantially subside for 10–12 days.</li><li>Buprenorphine withdrawal symptoms emerge within 3–5 days after the last dose of buprenorphine, and mild withdrawal features continue for up to several weeks.</li><li>Buprenorphine use may cause precipitated withdrawal in someone who has recently used heroin (less than 8 hours previously) or methadone (less than 24 hours previously). This typically occurs 1–3 hours after the first buprenorphine dose, peaking in severity over the first 3–6 hours.</li></ul></li><li>Check that the person has been given <a class=\"topic-reference internal-reference\" href=\"/topics/opioid-dependence/management/assessment/#information-advice\">information and advice</a> about harm reduction, especially about the dangers of injecting and overdose.</li><li><strong>Warn the person about the dangers of overdose if street drugs are used to alleviate symptoms, especially if injected</strong> — explain that loss of tolerance may lead to an unintentional overdose and death. </li><li><strong>Consider using lofexidine, which is licensed for the management of symptoms of opioid withdrawal </strong>—<strong> </strong>the treatment course is between 7–10 days with doses starting at 800 micrograms daily and rising to a maximum of 2.4 mg in divided doses. The dose is then reduced over subsequent days. </li><li><strong>Consider prescribing symptomatic treatment to help with the symptoms of withdrawal:</strong><ul><li>Diarrhoea — loperamide 4 mg immediately followed by 2 mg after each loose stool for up to five days. The usual dose is 6-8 mg daily, maximum 16 mg daily. </li><li>Nausea and or vomiting — metoclopramide 10 mg eight-hourly (for a maximum of five days to minimise neurological and other adverse reactions) or prochlorperazine 5 mg three times a day or 12.5 mg intramuscularly 12-hourly. </li><li>Stomach cramps — mebeverine 135 mg three times daily.</li><li>General aches and pains (for example, headache, muscular pains)— paracetamol, ibuprofen or other nonsteroidal anti-inflammatory drugs or topical rubefacients. </li><li>Agitation and anxiety, sleeplessness — diazepam (oral) up to 5–10 mg three times daily when required (or zopiclone 7.5 mg at bedtime for people who have been dependent on benzodiazepines).<ul><li>In severe cases of anxiety and agitation, obtain suitable psychiatric advice from an addiction psychiatrist or the on-call duty psychiatrist.</li></ul></li></ul></li></ul><!-- end field de8540cb-4745-48db-ae42-a75a00a5f2f7 --><!-- end item e5fc42a9-cdbb-4e04-9735-a75a00a5f327 -->","subChapters":[{"id":"04fb106f-5125-57ff-8ced-e584c0735266","slug":"basis-for-recommendation-c1e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field cb5f9e1c-edb5-49b9-ba96-a75a00a5f2fc --><h4>Basis for recommendation</h4><!-- end field cb5f9e1c-edb5-49b9-ba96-a75a00a5f2fc -->","summary":null,"htmlStringContent":"<!-- begin item c1e8e5fe-750d-44f9-a186-a75a00a5f2fc --><!-- begin field 674fe389-8917-49b9-9110-a75a00a5f2fc --><p>These recommendations are based on the Royal College of General Practitioners' <em>Guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">Ford et al, 2011</a>]<em>, </em>the Department of Health and devolved administrations' guideline <em>Drug misuse and dependence: UK guidelines on clinical management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>], the National Drug Strategy Australia (NDSA) <em>National guidelines for medication-assisted treatment of opioid dependence</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">NDSA, 2014</a>], and what CKS considers good clinical practice. </p><h5>Management of acute withdrawal [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>]</h5><ul><li>The recommendation not be pressurised into prescribing an opioid substitute in people with acute withdrawal syndrome is extrapolated from a section of the Department of Health guideline <em>Drug misuse and dependence: UK guidelines on clinical management</em> which relates to initial dosing for opioid-dependent people admitted to hospital, which states:<ul><li>Do not be pressured to initiate prescribing prematurely, but do carefully consider how to manage the balance of risks if a patient is developing opioid withdrawals that make it difficult for them to engage in their required medical/surgical/obstetric treatment.</li></ul></li><li>However, it also states that while opioid withdrawal symptoms are not generally life threatening, associated anxiety and distress may become very significant for some, particularly people who may have comorbid mental and physical health problems, so it is important that rapid assessment and safe prescribing of opioid substitution treatment is undertaken at the earliest opportunity.</li><li>The section on assessment of people for opioid substitution therapy advises that people who misuse drugs typically present for treatment at a time of crisis in their lives and may not respond well to an exhaustive interview at the initial stages. Nevertheless, clinicians need to gather sufficient information to properly and safely assess presenting problems, identify potential risks and guide treatment decisions, and there needs to be a balance that allows for the necessary information to be obtained efficiently, without adding delay and without placing the patient at risk of dropping out of treatment. Subsequent, more comprehensive assessment can take place over the following weeks during treatment optimisation.</li></ul><h5>Offering symptomatic treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>]</h5><ul><li><p>Prescribing symptomatically can reduce some of the physical effects of withdrawal. There is no systematic evidence that any of these medicines work to improve outcomes but they may be useful where it is not possible to prescribe effective opioid substitution.</p></li></ul><!-- end field 674fe389-8917-49b9-9110-a75a00a5f2fc --><!-- end item c1e8e5fe-750d-44f9-a186-a75a00a5f2fc -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}